Terns Pharmaceuticals Inc
430
Company Profile
Business description
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
Contact
1065 East Hillsdale Boulevard
Suite 100
FosterCA94404
USAT: +1 650 525-5535
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.90 | 0.10 | 0.00% |
| CAC 40 | 8,198.79 | 31.06 | 0.38% |
| DAX 40 | 24,276.75 | 71.39 | 0.29% |
| Dow JONES (US) | 48,739.41 | 238.14 | 0.49% |
| FTSE 100 | 10,609.31 | 41.66 | 0.39% |
| HKSE | 25,321.34 | 71.86 | 0.28% |
| NASDAQ | 22,807.48 | 290.79 | 1.29% |
| Nikkei 225 | 55,278.06 | 1,032.52 | 1.90% |
| NZX 50 Index | 13,617.89 | 86.77 | 0.64% |
| S&P 500 | 6,869.50 | 52.87 | 0.78% |
| S&P/ASX 200 | 8,940.30 | 3.10 | -0.03% |
| SSE Composite Index | 4,108.57 | 26.09 | 0.64% |